Why Is AstraZeneca (AZN) Stock Falling After a Successful Drug Trial?
TLDR
- AZN stock fell nearly 2% in pre-market trading despite positive trial news
- Tezspire met its primary and secondary endpoints in a late-stage eosinophilic esophagitis trial
- The drug reduced inflammation and improved swallowing difficulty compared to placebo
- Tezspire already generated $1.13 billion in sales in 2025 as an approved asthma treatment
- Wall Street holds a Strong Buy consensus on AZN with an average price target of $221.40, implying 33% upside
AstraZeneca stock dropped around 2% in pre-market trading Thursday, even as the company reported that its asthma drug Tezspire hit all its main goals in a late-stage trial for eosinophilic esophagitis.
The drug is developed in partnership with Amgen, whose stock also dipped on the news. Both stocks moved lower despite what was broadly a positive clinical update.
Tezspire met both the primary and secondary endpoints in the trial. The study showed the drug reduced inflammation in the esophagus and made swallowing easier for patients compared to a placebo.
โฆ Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
